Abstract
We studied the effect of transdermally applied scopolamine (scopolamine-TTS) on autonomic nervous activity during sleep. The double-blind, randomized, crossover study was carried out in six healthy male volunteers by applying 1.5 mg scopolamine-TTS or placebo patch on the retroauricular skin and by monitoring heart rate, cardiac ballistogram, respiration and body movements by using electrocardiogram and static charge sensitive bed.
Scopolamine did not decrease the time the subjects desired to sleep (516 min after TTS, 511 min after placebo) or the number of body movements of 3–5 s duration the subjects spontaneously performed during sleep (47 after TTS, 58 after placebo). No adverse effects of scopolamine were reported spontaneously. Scopolamine-TTS slowed the mean heart rate during quiet sleep from 53.2 to 44.9 beats · min−1, and increased the duration of bradycardia in response to body movements (MIB-reflex) from 12.5 to 14.7 s with a significant difference between scopolamine and placebo effects. The bradycardias were not associated with disturbances in cardiorespiratory or central nervous system functions. The cardiac vagomimetic action of scopolamine-TTS could be explained by low plasma drug concentrations (175 pg/ml) primarily blocking only neuronal inhibitory prejunctional muscarinic receptors which regulate acetylcholine release from the autonomic ganglia and parasympathetic nerve-endings.
Because of the central role of acetylcholine in the physiological regulation of sleep, the effect of scopolamine-TTS on sleep merits further investigations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brown JH (1990) Atropine, scopolamine, and related antimuscarinic drugs. In: Goodman and Gilman's pharmacological basis of therapeutics, 8th edn. Pergamon Press, Oxford New York, pp 151–165
Gadea-Ciria M, Stadler H, Llooyd KG, Bartholini G (1973) Acetylcholine release within the cat striatum during the sleep-wake-fulness cycle. Nature 243: 518–519
Shiromani PJ, Gillin JC, Henriksen SJ (1987) Cholinergic regulation of REM sleep. Annu Rev Pharmacol Toxicol 27: 137–156
Price NM, Schmitt LG, McGuire J, Shaw JE, Trobough G (1981) Transdermal scopolamine in the prevention of motion sickness. Clin Pharmacol Ther 29: 414–419
Marion WF van, Bongaerts MCM, Christiansen JC, Hofkamp HG, Ouwerkerk W van (1985) Influence of transdermal scopolamine on motion sickness during 7 days exposure to heavy seas. Clin Pharmacol Ther 38: 301–305
Groot AC de, Nater JP (1990) Transdermal therapeutic systems. Scopolamine. In: Dukes MNG, Beeley L (eds) Side-effects of drugs, Annual 14. Elsevier, Amsterdam New York Oxford, pp 130–131
Alihanka J, Vaahtoranta K, Saarikivi I (1981) A new method for long-term monitoring of the ballistocardiogram, heart rate, and respiration. Am J Physiol 240: R384-R392
Alihanka J (1982) Sleep movements and associated autonomic nervous activities. Acta Physiol Scand [Suppl 511]:8–73
Alihanka J (1987) Basic principles for analyzing and scoring Bio-Matt (SCSB) recordings. In: Annales Universitatis Turkuensis D 26. Typopress Oy, Turku, Finland
Kaila T, Ali-Melkkilä T, Iisalo E, Kanto J (1990) Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. Pharmacol Toxicol 67: 313–316
Dibner-Dunlap ME, Eckberg DL, Magid NM, Cintron-Trevino NM (1985) The long-term increase of baseline and reflexly augmented levels of human vagal-cardiac nervous activity induced by scopolamine. Circulation 71: 797–804
Kaila T, Antila K, Pihlajamäki K, Halkola L (1988) Scopolamine plasma levels and the control of heart rate. Abstracts of the XIX Nordic Congress of Physiology and Pharmacology, University of Oslo, Norway 13–15 June, p 71
Snyder F, Hobson JA, Morrison DF, Goldfranc (1964) Changes in respiration, heart rate and systolic blood pressure in human sleep. J Appl Physiol 19: 417–422
Kleiger RE, Miller JP, Bigger TJ Jr, Moss AJ, The Multicenter Post-Infarction Research Group (1987) Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 59: 256–262
Wellstein A, Pitschner HF (1988) Complex dose-response curve of atropine in man explained by different functions of M1- and M2-cholinoceptors. Naunyn Schmiedeberg's Arch Pharmacol 338: 19–27
Costa M, Majewski H (1991) Evidence for facilitatory and inhibitory muscarinic receptors on postganglionic sympathetic nerves in mouse isolated atria. Br J Pharmacol 102: 855–660
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Alihanka, J., Lahdenperä, A. & Kaila, T. The effects of transdermal scopolamine on autonomic nervous activity during sleep. Eur J Clin Pharmacol 46, 507–510 (1994). https://doi.org/10.1007/BF00196106
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00196106